SCOTTSDALE, Ariz.--(BUSINESS WIRE)--March 16, 2005--Medicis (NYSE:MRX) today announced that its Board of Directors declared a quarter-end cash dividend of $0.03 per issued and outstanding share of its Common Stock payable on April 29, 2005, to stockholders of record at the close of business on April 1, 2005.
Medicis is the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and podiatric conditions and aesthetics medicine. The Company is dedicated to helping patients attain a healthy and youthful appearance and self-image. Medicis has leading branded prescription products in a number of therapeutic categories, including acne, eczema, fungal infections, psoriasis, rosacea, seborrheic dermatitis and skin and skin-structure infections. The Company's products have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance.
